title: Aneuploidy screening in the first trimester.
abstract: This article reviews the performance of first trimester screening for chromosomal anomalies using various combinations of ultrasound and maternal serum biochemical modalities. Detection rates in excess of 90% can be routinely achieved for Trisomy 21, Trisomy 13, Trisomy 18 using a combination of fetal nuchal translucency (NT) thickness and maternal serum free ss-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks of gestation.
authors.affiliation: Prenatal Screening Unit, Clinical Biochemistry Department, Harold Wood Hospital, Romford, UK. kevinspencer1@aol.com
authors.forename: Kevin
authors.initials: K
authors.lastname: Spencer
mesh_terms: D051722:ADAM Proteins / Q000097:blood; D000072199:ADAM12 Protein; D000782:Aneuploidy; D015415:Biomarkers / Q000097:blood; D004314:Down Syndrome / Q000175:diagnosis; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis*; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A; D011296:Prenatal Diagnosis; D016216:Ultrasonography, Prenatal
chemical_list: D015415:Biomarkers; D008565:Membrane Proteins; D051722:ADAM Proteins; D000072199:ADAM12 Protein; C000606480:ADAM12 protein, human; D011266:Pregnancy-Associated Plasma Protein-A